Shanghai Rendu Biotechnology Co

Shanghai Rendu Biotechnology Co Net Debt/Equity

The Net Debt to Equity Ratio of Shanghai Rendu Biotechnology Co (688193.SS) as of Nov 3, 2026 is -0.64.

Net Debt/Equity

-0.64

Last updated:

Net Debt to Equity Ratio of Shanghai Rendu Biotechnology Co is 2018 -0.64 . Net Debt to Equity Ratio of Shanghai Rendu Biotechnology Co was 2017 - . It decreases by % lower compared to the previous year.

The Shanghai Rendu Biotechnology Co Net Debt/Equity history

The Shanghai Rendu Biotechnology Co Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Rendu Biotechnology Co Stock analysis

What does Shanghai Rendu Biotechnology Co do? Shanghai Rendu Biotechnology Co., Ltd. generates revenue through the sale of molecular diagnostic tests and medical instruments. The company develops diagnostic reagents using RNA isothermal amplification technology, including respiration series, reproduction series, enterovirus series, and blood-borne diseases series. These products are sold domestically within China, targeting healthcare providers and laboratories that require rapid and accurate diagnostic solutions. The firm's focus on domestic market sales ensures consistent demand for its specialized reagents and instruments. The company's product portfolio includes multiple series of diagnostic reagents designed for specific health conditions, such as respiratory and reproductive health. Medical instruments are also manufactured and sold alongside these reagents. Domestic sales within China form the primary revenue stream, with no mention of international markets or additional product lines. The firm's technology and product offerings cater to the needs of medical professionals seeking efficient diagnostic tools. Shanghai Rendu Biotechnology's business model relies on the domestic market for all product sales, with no indication of export or international partnerships. The company's workforce of 528 full-time employees supports the development, manufacturing, and sales of its diagnostic reagents and instruments. Revenue is derived solely from the sale of these products within China, without any reference to third-party collaborations or additional services. Shanghai Rendu Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Rendu Biotechnology Co stock

Net Debt to Equity Ratio of Shanghai Rendu Biotechnology Co is -0.64 in 2018.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Shanghai Rendu Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Shanghai Rendu Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Shanghai Rendu Biotechnology Co

All Key Metrics — Shanghai Rendu Biotechnology Co